Clinical Trial Update: Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ticagrelor to high-dose clopidogrel in patients with high platelet reactivity on clopidogrel after PCI has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Coronary Artery Disease | Phase 3 | Status: WITHDRAWN